Możliwości terapeutyczne w leczeniu jaskry otwartego kąta i ich zastosowanie w oparciu o najnowsze wytyczne Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2024
Słowa kluczowe:
jaskra, terapia farmakologiczna, leki w jaskrze, leki złożone
##plugins.themes.bootstrap3.article.main##
Abstrakt
Jaskra to neuropatia nerwu wzrokowego, która charakteryzuje się typowym uszkodzeniem nerwu wzrokowego ze stopniowym zanikiem komórek zwojowych siatkówki i ubytkami w polu widzenia. Celem farmakoterapii jaskry jest obniżenie ciśnienia wewnątrzgałkowego i zmniejszenie dobowych fluktuacji. Obecnie w leczeniu jaskry pierwotnej otwartego kąta w Polsce stosujemy cztery grupy leków: antagonistów receptorów β-adrenergicznych, analogi prostaglandyn, agonistów receptorów α-adrenergicznych i inhibitory anhydrazy węglanowej. Lekami pierwszego rzutu, według wytycznych Polskiego Towarzystwa Okulistycznego, są analogi prostaglandyn/prostamidy. Jeśli rozważane jest dołączenie drugiego leku do prostaglandyn, należy pamiętać, że brymonidyna obniża ciśnienie wewnątrzgałkowe silniej niż dorzolamid i brynzolamid, a podobnie jak tymolol. Leki zawierające dwie substancje czynne są tak samo skuteczne jak substancje podawane w dwóch osobnych preparatach, dlatego korzystne jest stosowanie preparatów złożonych zamiast zakraplania dwóch różnych leków.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Misiuk-Hojło M, Tomczyk-Socha M. Możliwości terapeutyczne w leczeniu jaskry otwartego kąta i ich zastosowanie w oparciu o najnowsze wytyczne. Ophthatherapy [Internet]. 31 marzec 2024 [cytowane 18 maj 2024];00. Dostępne na: https://www.journalsmededu.pl/index.php/ophthatherapy/article/view/3058
Numer
Dział
Terapie zachowawcze
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Treatment Options. In: Terminology and guidelines for glaucoma. 5th ed. European Glaucoma Society, Publicomm, Savona 2020: 127-56.
2. Szumny D, Misiuk-Hojło M. Leki stosowane w leczeniu jaskry. In: Prost M, Jachowicz R, Nowak J (ed). Kliniczna farmakologia okulistyczna. Elsevier, Wrocław 2013: 190-207.
3. Farmakoterapia jaskry. In: Rękas M (ed). Jaskra. Seria Basic and Clinical Science Course. 2nd ed. Edra Urban & Partner, Wrocław 2018: 181-204.
4. Polskie Towarzystwo Okulistyczne. Wytyczne diagnostyki i leczenia jaskry (aktualizacja 2022).
5. Stewart WC, Konstas AG, Nelson LA et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008; 115(7): 1117-22.e1. http://doi.org/10.1016/j.ophtha.2007.10.004.
6. Leske MC, Heijl A, Hyman L et al. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999; 106(11): 2144-53. http://doi.org/10.1016/s0161-6420(99)90497-9.
7. Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology. 2009; 116(9): 1719-24. http://doi.org/10.1016/j.ophtha.2009.03.050.
8. Pfeiffer N; European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002; 240(11): 893-9. http://doi.org/10.1007/s00417-002-0553-0.
9. Higginbotham EJ, Feldman R, Stiles M et al.; Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002; 120(7): 915-22. http://doi.org/10.1001/archopht.120.7.915.
10. Toumanidou V, Diafas A, Georgiadis N et al. Fixed versus Unfixed Combination of Topical Latanoprost/Timolol for Glaucoma: An Observational Study Investigating the Level of Adherence and Ocular Surface Health. J Clin Med. 2023; 12(9): 3137. http://doi.org/10.3390/jcm12093137.
11. Barnebey HS, Orengo-Nania S, Flowers BE et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005; 140(1): 1-7. http://doi.org/10.1016/j.ajo.2005.02.043.
12. Hommer A; Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007; 17(1): 53-62. http://doi.org/10.1177/112067210701700108.
13. Konstas AG, Katsanos A, Athanasopoulos GP et al. Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients. Expert Opin Pharmacother. 2018; 19(18): 1981-8. http://doi.org/10.1080/14656566.2018.1534958.
14. Sherwood MB, Craven ER, Chou C. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006; 124(9): 1230-8. http://doi.org/10.1001/archopht.124.9.1230.
15. Frampton JE. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension. Drugs Aging. 2006; 23(9): 753-61. http://doi.org/10.2165/00002512-200623090-00005.
16. Razeghinejad MR, Sawchyn AK, Katz LJ. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Expert Opin Pharmacother. 2010; 11(6): 959-68. http://doi.org/10.1517/14656561003667540.
17. Nixon DR, Yan DB, Chartrand JP et al. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin. 2009; 25(7): 1645-53. http://doi.org/10.1185/03007990902994041.
18. Sall KN, Greff LJ, Johnson-Pratt LR et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology. 2003; 110(3): 615-24. http://doi.org/10.1016/S0161-6420(02)01900-0.
19. Hatanaka M, Grigera DE, Barbosa WL et al. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. J Glaucoma. 2008; 17(8): 674-9. http://doi.org/10.1097/IJG.0b013e318168f008.
20. Boyle JE, Ghosh K, Gieser DK et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 1998; 105(10): 1945-51. http://doi.org/10.1016/s0161-6420(98)91046-6.
21. Strohmaier K, Snyder E, DuBiner H et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology. 1998; 105(10): 1936-44. http://doi.org/10.1016/s0161-6420(98)91045-4.
22. Kaback M, Scoper SV, Arzeno G et al. Brinzolamide 1%/Timolol 0.5% Study Group. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology. 2008; 115(10): 1728-34, 1734.e1-2. http://doi.org/10.1016/j.ophtha.2008.04.011.
23. Januleviciene I. Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma. Curr Med Res Opin. 2010; 26(11): 2575-8. http://doi.org/10.1185/03007995.2010.517718.
2. Szumny D, Misiuk-Hojło M. Leki stosowane w leczeniu jaskry. In: Prost M, Jachowicz R, Nowak J (ed). Kliniczna farmakologia okulistyczna. Elsevier, Wrocław 2013: 190-207.
3. Farmakoterapia jaskry. In: Rękas M (ed). Jaskra. Seria Basic and Clinical Science Course. 2nd ed. Edra Urban & Partner, Wrocław 2018: 181-204.
4. Polskie Towarzystwo Okulistyczne. Wytyczne diagnostyki i leczenia jaskry (aktualizacja 2022).
5. Stewart WC, Konstas AG, Nelson LA et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008; 115(7): 1117-22.e1. http://doi.org/10.1016/j.ophtha.2007.10.004.
6. Leske MC, Heijl A, Hyman L et al. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999; 106(11): 2144-53. http://doi.org/10.1016/s0161-6420(99)90497-9.
7. Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology. 2009; 116(9): 1719-24. http://doi.org/10.1016/j.ophtha.2009.03.050.
8. Pfeiffer N; European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002; 240(11): 893-9. http://doi.org/10.1007/s00417-002-0553-0.
9. Higginbotham EJ, Feldman R, Stiles M et al.; Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002; 120(7): 915-22. http://doi.org/10.1001/archopht.120.7.915.
10. Toumanidou V, Diafas A, Georgiadis N et al. Fixed versus Unfixed Combination of Topical Latanoprost/Timolol for Glaucoma: An Observational Study Investigating the Level of Adherence and Ocular Surface Health. J Clin Med. 2023; 12(9): 3137. http://doi.org/10.3390/jcm12093137.
11. Barnebey HS, Orengo-Nania S, Flowers BE et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005; 140(1): 1-7. http://doi.org/10.1016/j.ajo.2005.02.043.
12. Hommer A; Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007; 17(1): 53-62. http://doi.org/10.1177/112067210701700108.
13. Konstas AG, Katsanos A, Athanasopoulos GP et al. Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients. Expert Opin Pharmacother. 2018; 19(18): 1981-8. http://doi.org/10.1080/14656566.2018.1534958.
14. Sherwood MB, Craven ER, Chou C. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006; 124(9): 1230-8. http://doi.org/10.1001/archopht.124.9.1230.
15. Frampton JE. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension. Drugs Aging. 2006; 23(9): 753-61. http://doi.org/10.2165/00002512-200623090-00005.
16. Razeghinejad MR, Sawchyn AK, Katz LJ. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Expert Opin Pharmacother. 2010; 11(6): 959-68. http://doi.org/10.1517/14656561003667540.
17. Nixon DR, Yan DB, Chartrand JP et al. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin. 2009; 25(7): 1645-53. http://doi.org/10.1185/03007990902994041.
18. Sall KN, Greff LJ, Johnson-Pratt LR et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology. 2003; 110(3): 615-24. http://doi.org/10.1016/S0161-6420(02)01900-0.
19. Hatanaka M, Grigera DE, Barbosa WL et al. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. J Glaucoma. 2008; 17(8): 674-9. http://doi.org/10.1097/IJG.0b013e318168f008.
20. Boyle JE, Ghosh K, Gieser DK et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 1998; 105(10): 1945-51. http://doi.org/10.1016/s0161-6420(98)91046-6.
21. Strohmaier K, Snyder E, DuBiner H et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology. 1998; 105(10): 1936-44. http://doi.org/10.1016/s0161-6420(98)91045-4.
22. Kaback M, Scoper SV, Arzeno G et al. Brinzolamide 1%/Timolol 0.5% Study Group. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology. 2008; 115(10): 1728-34, 1734.e1-2. http://doi.org/10.1016/j.ophtha.2008.04.011.
23. Januleviciene I. Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma. Curr Med Res Opin. 2010; 26(11): 2575-8. http://doi.org/10.1185/03007995.2010.517718.